[Observation of long-term therapeutic outcome in chronic granulocytic leukemia].
OBJECTIVE
To analyse the long-term outcome of various therapeutic protocol for the treatment of chronic granulocytic leukemia (CGL).


METHODS
Median duration of chronic phase, survival and transformation of 331 CGL patients treated with different project were retrospectively analyzed.


RESULTS
Longer chronic phase and survival and lower percentage of transformation were found in patients using mesoindigo as maintaining treatment as compared with those using busulfan as maintaining treatment. The effect of meisoindigo and hydroxyurea showed no significant difference. These two drugs were both superior to bulsufan. Combination chemotherapy was not superior to meisoindigo, hydroxyurea or busulfan alone. Interferon had the best therapeutic effectiveness for the treatment of CGL.


CONCLUSIONS
Busulfan was not suitable for maintaining treatment. Meisoindigo or meisoindigo combined with hydroxyurea was good choices for maintaining treatment. Meisoindigo and hydroxyurea had better effect in combination than alone. Interferon could significantly prolong the chronic period and survival period of CGL patients.
Liu
B
B
Institute of Hematology, CAMS and PUMC, Tianjin 300020, China.
Wang
Y
Y
Hao
C
C
Liu
Y
Y
Qian
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D018906:Antineoplastic Agents, Alkylating; D002066:Busulfan